Nonbenzodiazepine

Background

Nonbenzodiazepines have demonstrated efficacy in treating sleep disorders. There is some limited evidence that suggests that tolerance to nonbenzodiazepines is slower to develop than with benzodiazepines. However, data is limited so no conclusions can be drawn. Data is also limited into the long-term effects of nonbenzodiazepines. Further research into the safety of nonbenzodiazepines and long-term effectiveness of nonbenzodiazepines has been recommended in a review of the literature. Some differences exist between the Z-drugs, for example tolerance and rebound effects may not occur with zaleplon.

Classes

Currently, the major chemical classes of nonbenzodiazepines are:

Imidazopyridines

• Alpidem
• Necopidem
• Saripidem
• Zolpidem (Ambien, Ambien CR, Intermezzo, Zolpimist, Edluar, Ivadal, Sanval, Stilnox, etc.) Pyrazolopyrimidines
• Divaplon
• Fasiplon
• Indiplon
• Lorediplon
• Ocinaplon
• Panadiplon
• Taniplon
• Zaleplon (Sonata, Starnoc, Andante) Cyclopyrrolones
• Eszopiclone (Lunesta, Valnoc, etc.)
• Pagoclone
• Pazinaclone
• Suproclone
• Suriclone
• Zopiclone (Imovane, Zimovane, Somnol, etc.) β-Carbolines
• Abecarnil
• Azocarnil (photoswitchable)
• Gedocarnil
• SL-651,498
• ZK-93423 Others
• AXS-17 (BAER-101, AZD-7325)
• CGS-20625
• CGS-9896
• CL-218,872
• ELB-139
• GBLD-345
• HIE-124
• L-838,417
• NS-2664
• NS-2710
• Pipequaline
• RWJ-51204
• SB-205,384
• SL-651,498
• SX-3228
• TCS-1205
• TP-003
• TP-13
• TPA-023
• Y-23684
• Etifoxine

Pharmacology

The nonbenzodiazepines are positive allosteric modulators of the GABAA receptor. Like the benzodiazepines, they exert their effects by binding to and activating the benzodiazepine site of the receptor complex.

Functional selectivity

Some nonbenzodiazepines can be subtype-selective, possibly providing anxiolytic effects with little to no hypnotic or amnesic effects or providing hypnotic effects with little or no anxiolytic effect.

More recently, a range of non-sedating anxiolytic drugs derived from the same structural families as the Z-drugs have been developed, such as alpidem (Ananxyl) and pagoclone, and approved for clinical prescription. The new drugs are much more selective than the older benzodiazepine anxiolytics, producing effective relief of anxiety/panic with little or no sedation, anterograde amnesia, or anticonvulsant effects, and are thus potentially more precise than older, anti-anxiety drugs. However, anxiolytic nonbenzodiazepines are not widely prescribed and many have collapsed after initial clinical trials and consumption halted many projects, including but not limited to alpidem, indiplon, and suriclone.

A number of non-sedating benzodiazepine anxiolytics such as imidazenil and clobazam also exist, with the caveat that neither is a traditional 1,4-benzodiazepine. The functional selectivity is not unique to the nonbenzodiazepine structural class and has more to do with selectivity among different types of GABAA receptors or partial agonism, though this structural class does have more drug candidates.

Pharmaceuticals

The first three nonbenzodiazepine drugs to enter the market were the "Z-drugs", zopiclone, zolpidem and zaleplon. These three drugs are all sedatives used exclusively for the treatment of mild insomnia. They are safer than the older barbiturates especially in overdosage and they may, when compared to the benzodiazepines, have less of a tendency to induce physical dependence and addiction, although these issues can still become a problem. This has led to the Z-drugs becoming widely prescribed for the treatment of insomnia particularly in elderly patients. Almost a third of all prescriptions written for Z-drugs are for adults over the age of 65.

Long-term use is not recommended as tolerance and addiction can occur. Zolpidem and zaleplon are, in the US, indicated for 7–10 days of use only. Longer periods of use lead to loss of efficacy from tolerance. Tolerance has also been demonstrated with zopiclone, which is indicated for a maximum of 4 weeks of use in New Zealand.

A survey of patients using nonbenzodiazepine Z-drugs and benzodiazepine hypnotic users found that there was no difference in reports of adverse effects that were reported in over 41% of users and, in fact, Z-drug users were more likely to report that they had tried to quit their hypnotic drug and were more likely to want to stop taking Z-drugs than benzodiazepine users. Efficacy also did not differ between benzodiazepine and Z-drug users.

Effectiveness

A major systematic review and network meta-analysis of medications for the treatment of insomnia was published in 2022. It included the Z-drugs and found effect sizes (standardized mean difference (SMD)) ranging from 0.03 to 0.63 for these agents. More specifically, the SMDs were 0.45 (4weeks) and 0.03 (3months) for zolpidem, 0.51 (4weeks) for zopiclone, 0.51 (4weeks) and 0.63 (3months) for eszopiclone, and 0.19 (4weeks) for zaleplon. Eszopiclone had the most favorable profile and best evidence to support its use. For comparison, benzodiazepines had SMDs of 0.58 to 0.83, sedative antidepressants and antihistamines had SMDs of 0.30 to 0.55, the antipsychotic quetiapine had an SMD of 0.07, orexin receptor antagonists had SMDs of 0.23 to 0.44, and melatonin receptor agonists had SMDs of 0.00 to 0.13. The certainty of evidence varied and ranged from high to very low depending on the medication.

Side effects

The Z-drugs are not without disadvantages, and all three compounds are notable for producing side effects such as pronounced amnesia and more rarely hallucinations, especially when used in large doses. On rare occasions, these drugs can produce a fugue state, wherein the patient sleepwalks and may perform relatively complex actions, including cooking meals or driving cars, while effectively unconscious and with no recollection of the events upon awakening. While this effect is rare (and has also been reported to occur with some of the older sedative drugs such as temazepam and secobarbital), it can be potentially hazardous, and so further development of this class of drugs has continued in an effort to find new compounds with further improved profiles.

Daytime withdrawal-related anxiety can also occur from chronic nightly nonbenzodiazepine hypnotic usage such as with zopiclone.

Side effects can differ within the drug class due to differences in metabolism and pharmacology. For example, long-acting benzodiazepines have problems of drug accumulation especially in the elderly or those with liver disease, and shorter-acting benzodiazepines have a higher risk of more severe withdrawal symptoms. In the case of the nonbenzodiazepines, zaleplon may be the safest in terms of next-day sedation, and − unlike zolpidem and zopiclone − zaleplon has been found to have no association with increased motor vehicle accidents even when taken for middle-of-the-night insomnia due to its ultrashort elimination half-life.

Increased risk of depression

It has been claimed that insomnia causes depression and hypothesized that insomnia medications may help to treat depression. However, an analysis of data of clinical trials submitted to the Food and Drug Administration (FDA) concerning the drugs zolpidem, zaleplon, and eszopiclone found that these sedative hypnotic drugs more than doubled the risks of developing depression compared to those taking placebo pills. Hypnotic drugs, therefore, may be contraindicated in patients with or at risk of depression. Hypnotics were found to be more likely to cause depression than to help it. Studies have found that long-term users of sedative hypnotic drugs have a markedly raised suicide risk as well as an overall increased mortality risk. Cognitive-behavioral therapy (CBT) for insomnia, on the other hand, has been found to both improve sleep quality as well as general mental health.

Other risks

Sleeping pills, including the Z-drugs, have been associated with an increased risk of death.

In older people this family of medications increases the risk of fractures and falls. The 2023 Beers criteria lists all three Z-drugs approved in the US (zolpidem, zaleplon, eszolpiclon) as unsuitable for older people.

The Z-drug zaleplon may have fewer side effects compared to benzodiazepines.

Much like benzodiazepines, Z-drugs are associated with an increased incidence of dementia. There is overall a 20% increase in dementia risk after adjusting for confounding factors. The effect is more profound in women.

Dependence and withdrawal management

Nonbenzodiazepines should not be discontinued abruptly if taken for more than a few weeks due to the risk of rebound withdrawal effects and acute withdrawal reactions, which may resemble those seen during benzodiazepine withdrawal. Treatment usually entails gradually reducing the dosage over a period of weeks or several months depending on the individual, dosage, and length of time the drug has been taken. If this approach fails, a crossover to a benzodiazepine equivalent dose of a long-acting benzodiazepine (such as chlordiazepoxide or more preferably diazepam) can be tried followed by a gradual reduction in dosage. In extreme cases and, in particular, where severe addiction and/or abuse is manifested, an inpatient detoxification may be required, with flumazenil as a possible detoxification tool.

Elderly

Nonbenzodiazepine hypnotic drugs, similar to benzodiazepines, cause impairments in body balance and standing steadiness upon waking; falls and hip fractures are frequently reported. The combination with alcohol increases these impairments. Partial but incomplete tolerance develops to these impairments. In general, nonbenzodiazepines are not recommended for older patients due to the increased risk of falls and fractures. An extensive review of the medical literature regarding the management of insomnia and the elderly found that there is considerable evidence of the effectiveness and lasting benefits of non-drug treatments for insomnia in adults of all age groups and that these interventions are underused. Compared with the benzodiazepines, the nonbenzodiazepine sedative-hypnotics offer little if any advantages in efficacy or tolerability in elderly persons. It was found that newer agents such as the melatonin agonists may be more suitable and effective for the management of chronic insomnia in elderly people. Long-term use of sedative-hypnotics for insomnia lacks an evidence base and is discouraged for reasons that include concerns about such potential adverse drug effects as cognitive impairment (anterograde amnesia), daytime sedation, motor incoordination, and increased risk of motor vehicle accidents and falls. In addition, the effectiveness and safety of long-term use of these agents remain to be determined. It was concluded that further research is needed to evaluate the long-term effects of treatment and the most appropriate management strategy for elderly persons with chronic insomnia.

Safety

A review of the literature regarding hypnotics including the nonbenzodiazepine Z-drugs concluded that these drugs carry a significant risk to the individual. The risks include dependence, accidents, and other adverse effects. Gradual discontinuation of hypnotics may lead to improved health without worsening of sleep. It is preferred that they should be prescribed for only a few days at the lowest effective dose and avoided wherever possible in the elderly.

History

Z-drugs emerged in the last years of the 1980s and early 1990s, with zopiclone (Imovane) approved by the British National Health Service as early as 1989, quickly followed by Sanofi with zolpidem (Ambien). By 1999, King Pharmaceuticals had finalized approval with the American Food and Drug Administration (FDA) to market zaleplon (Sonata, Starnoc) across the US. In 2005, the FDA approved eszopiclone (Lunesta) the (S)-enantiomer of zopiclone. That same year, 2005, the FDA finalized approval for Ambien CR, or extended-release zolpidem. Most recently, in 2012 the FDA approved Intermezzo (zolpidem tartate sublingual), which is marketed for middle-of-the-night insomnia, available in doses only half of the strength of immediate-release zolpidem tartrate to avoid residual next-day sedation.

References

References

1. (December 2004). "What's wrong with prescribing hypnotics?". Drug and Therapeutics Bulletin.
2. (November 2012). "Anxioselective anxiolytics: on a quest for the Holy Grail". Trends Pharmacol Sci.
3. (December 2006). "GPs' attitudes to benzodiazepine and 'Z-drug' prescribing: a barrier to implementation of evidence and guidance on hypnotics". The British Journal of General Practice.
4. (June 1998). "Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia". The Annals of Pharmacotherapy.
5. Owens, Judith A.. (2014-01-01). "Chapter 7 - Pharmacology of Sleep". W.B. Saunders.
6. (March 2005). "Diagnosis and treatment of chronic insomnia: a review". Psychiatric Services.
7. (January 2001). "Implications of hypnotic flexibility on patterns of clinical use". International Journal of Clinical Practice. Supplement.
8. (October 2024). "Light-Activated Agonist-Potentiator of GABA_A Receptors for Reversible Neuroinhibition in Wildtype Mice". Journal of the American Chemical Society.
9. (January 2012). "Evaluating Newer Sleeping Pills Used to Treat: Insomnia: Comparing Effectiveness, Safety, and Price". Consumer Reports.
10. (December 2012). "Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration". BMJ.
11. (2006). "New approaches in managing chronic insomnia". CNS Spectrums.
12. (April 2006). "Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia". Clinical Therapeutics.
13. (2007). "Update on the safety considerations in the management of insomnia with hypnotics: incorporating modified-release formulations into primary care". Primary Care Companion to the Journal of Clinical Psychiatry.
14. (June 2016). "Trends in prescribing of sedative-hypnotic medications in the USA: 1993-2010". Pharmacoepidemiology and Drug Safety.
15. (July 2007). "[Sleep disorders and hypnotic agents: medical, social and economical impact]". Annales Pharmaceutiques Françaises.
16. "Literature Review of Nonbenzodiazepine Hypnotics".
17. (2009-08-15). "Sleep and sleep disorders in chronic users of zopiclone and drug-free insomniacs.". Journal of Clinical Sleep Medicine.
18. "Zopiclone – Indicated for short-term use only".
19. (June 2008). "Magic bullets for insomnia? Patients' use and experiences of newer (Z drugs) versus older (benzodiazepine) hypnotics for sleep problems in primary care". The British Journal of General Practice.
20. (July 2022). "Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis". Lancet.
21. (April 2008). "Dose-related illusions and hallucinations with zaleplon". Clinical Toxicology.
22. (2000). "Central nervous system side effects associated with zolpidem treatment". Clinical Neuropharmacology.
23. (November 2006). "[Are z-hypnotics better and safer sleeping pills than benzodiazepines?]". Tidsskrift for den Norske Laegeforening.
24. (June 2005). "One rare side effect of zolpidem--sleepwalking: a case report". Archives of Physical Medicine and Rehabilitation.
25. (March 2005). "Medication-associated somnambulism". Journal of the American Academy of Child and Adolescent Psychiatry.
26. (July 2002). "Amnestic sleep-related eating disorder associated with zolpidem". Sleep Medicine.
27. (August 2004). "Zaleplon overdose associated with sleepwalking and complex behavior". Journal of the American Academy of Child and Adolescent Psychiatry.
28. (July 1990). "Zopiclone and triazolam in insomnia associated with generalized anxiety disorder: a placebo-controlled evaluation of efficacy and daytime anxiety". International Clinical Psychopharmacology.
29. (June 1977). "Clinical implications of benzodiazepine pharmacokinetics". The American Journal of Psychiatry.
30. (January 1986). "Seizures following the withdrawal of alprazolam". The Journal of Nervous and Mental Disease.
31. (January 2001). "A general model of the effects of sleep medications on the risk and cost of motor vehicle accidents and its application to France". PharmacoEconomics.
32. (March 2002). "Differential residual effects of zaleplon and zopiclone on actual driving: a comparison with a low dose of alcohol". Sleep.
33. (January–February 2000). "Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia". Clinical Neuropharmacology.
34. (August 2004). "Residual effects of sleep medication on driving ability". Sleep Medicine Reviews.
35. (August 2007). "Greater incidence of depression with hypnotic use than with placebo". BMC Psychiatry.
36. (February 2016). "Mortality Risk of Hypnotics: Strengths and Limits of Evidence". Drug Safety.
37. (March 2018). "Z-drugs and risk for falls and fractures in older adults-a systematic review and meta-analysis". Age and Ageing.
38. (July 2023). "American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults". Journal of the American Geriatrics Society.
39. (2005). "Benefit-risk assessment of zaleplon in the treatment of insomnia". Drug Safety.
40. (19 April 2022). "Benzodiazepine and Z-Drug Use and the Risk of Developing Dementia.". The International Journal of Neuropsychopharmacology.
41. MedlinePlus. (January 8, 2001). "Eszopiclone". National Institutes of Health.
42. Professor Heather Ashton. "Benzodiazepines: How They Work and How to Withdraw".
43. (September 2005). "Dependence on zolpidem: two case reports of detoxification with flumazenil infusion". International Clinical Psychopharmacology.
44. (August 2010). "Effect of hypnotic drugs on body balance and standing steadiness". Sleep Medicine Reviews.
45. (August 2006). "The art of prescribing. Risks and benefits of non-benzodiazepine receptor agonists in the treatment of acute primary insomnia in older adults". Perspectives in Psychiatric Care.
46. (June 2006). "Management of chronic insomnia in elderly persons". The American Journal of Geriatric Pharmacotherapy.
47. (December 2004). "What's wrong with prescribing hypnotics?". Drug and Therapeutics Bulletin.